Lewin G R, Rueff A, Mendell L M
Department of Neurobiology and Behavior, SUNY at Stony Brook 11794.
Eur J Neurosci. 1994 Dec 1;6(12):1903-12. doi: 10.1111/j.1460-9568.1994.tb00581.x.
Mechanisms underlying the hyperalgesia induced by a single systemic injection of nerve growth factor (NGF) in adult rats were studied in vivo. A single dose of NGF initiated a prolonged thermal hyperalgesia to a radiant heat source within minutes that lasted for days. Animals which had been pretreated with the mast cell degranulating compound 48/80 or either one of two specific 5-hydroxytryptamine receptor antagonists (ICS 205-930 and methiothepin) also developed an NGF-induced thermal hyperalgesia, but onset was delayed by more than 3 h. In the presence of ICS 205-930 or methiothepin the early component NGF-induced hyperalgesia was reversed and the animals responded with an initial hypoalgesia to the thermal stimuli. Whereas these results indicate a peripheral mechanism for the initial thermal hyperalgesia, the later phase (7 h-4 days after NGF) appeared to be centrally maintained, since it could be selectively blocked by the non-competitive NMDA receptor antagonist MK-801. In contrast to the almost immediate thermal hyperalgesia following a single injection of NGF, a significant mechanical hyperalgesia began only after a 7 h latency. This NGF-induced mechanical hyperalgesia was not blocked by any of the treatments that attenuated the thermal hyperalgesia, indicating that a separate mechanism may be involved. Additional electrophysiological experiments showed that NGF-induced hyperalgesia was not maintained by an increased amount of spontaneous activity in C-fibres. A final result showed that endogenous release of NGF in a model of acute inflammation (complete Freund's adjuvant-induced inflammation) may be involved in the development of thermal hyperalgesia, since it could be blocked by concomitant treatment with anti-NGF antisera. These data indicate that NGF-induced thermal and mechanical hyperalgesia are mediated by different mechanisms. The rapid onset component of thermal hyperalgesia is due to a peripheral mechanism involving the degranulation of mast cells, whereas the late component involves central NMDA receptors. In contrast, the NGF-induced mechanical hyperalgesia seems to be independent of mast cell degranulation or central NMDA receptor sites.
在成年大鼠体内研究了单次全身注射神经生长因子(NGF)诱导痛觉过敏的机制。单次注射NGF后几分钟内即可引发对辐射热源的长时间热痛觉过敏,并持续数天。预先用肥大细胞脱颗粒化合物48/80或两种特异性5-羟色胺受体拮抗剂(ICS 205-930和甲硫噻平)之一处理的动物也会出现NGF诱导的热痛觉过敏,但起效延迟超过3小时。在存在ICS 205-930或甲硫噻平的情况下,NGF诱导的痛觉过敏早期成分会逆转,动物对热刺激最初表现为痛觉减退。虽然这些结果表明初始热痛觉过敏存在外周机制,但后期阶段(NGF注射后7小时至4天)似乎由中枢维持,因为它可被非竞争性NMDA受体拮抗剂MK-801选择性阻断。与单次注射NGF后几乎立即出现的热痛觉过敏不同,显著的机械性痛觉过敏仅在延迟7小时后才开始。这种NGF诱导的机械性痛觉过敏不受任何减轻热痛觉过敏治疗的阻断,表明可能涉及一种独立机制。额外的电生理实验表明,NGF诱导的痛觉过敏并非由C纤维中自发活动量增加所维持。最终结果表明,急性炎症模型(完全弗氏佐剂诱导的炎症)中NGF的内源性释放可能参与热痛觉过敏的发生,因为同时用抗NGF抗血清治疗可阻断其发生。这些数据表明,NGF诱导的热痛觉过敏和机械性痛觉过敏由不同机制介导。热痛觉过敏的快速起效成分是由于涉及肥大细胞脱颗粒的外周机制,而后期成分涉及中枢NMDA受体。相比之下,NGF诱导的机械性痛觉过敏似乎与肥大细胞脱颗粒或中枢NMDA受体位点无关。